Clinical Trials Browser

Phase 2 × Not yet recruiting × dalpiciclib × Clear all

NCT07307287 2025-12-29

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2 Not yet recruiting

HR+/HER2- Advanced Breast Cancer

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT06199271 2024-01-22

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05431504 2022-06-24

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Phase 2 Not yet recruiting

Advanced Breast Cancer